ArticleFrontiers in nutrition2025
Establishment and evaluation of a novel practical tool for the screening of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major comorbidity in type 2 diabetes mellitus (T2DM), yet early prediction models tailored to this population are limited. This study aimed to develop and validate a novel diagnostic predictive model for MASLD in adults with T2DM. Methods: A total of 4,726 T2DM patients were retrospectively analyzed. Candidate predictors were screened by least absolute shrinkage and selection operator (LASSO) regression, and a multivariable logistic regression model was built. Significant variables were integrated into a diagnostic predictive nomogram (DPN), with online and Excel-based calculators developed. Model performance was comprehensively evaluated and compared with four established models for fatty liver disease across training, internal, and external (NHANES) validation datasets. Subgroup analyses assessed generalizability. Results: Eight independent predictors (sex, age, body mass index, alanine aminotransferase, albumin, diabetes duration, triglycerides, and high-density lipoprotein cholesterol) were included in the final model. The DPN achieved robust discrimination in training set (AUC: 0.775, 95% CI: 0.759-0.791), validation set (0.767, 95% CI: 0.742-0.791), and test set (0.794, 95% CI: 0.749-0.839) compared to existing models. NRI and IDI confirmed improved predictive capacity ( Conclusions: The DPN is a clinically practical and resource-efficient screening tool that enables early risk stratification for MASLD in patients with T2DM. Its implementation could streamline screening pathways and facilitate timely intervention in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.